Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

MeiraGTx Holdings stock price, quote, forecast and news

MGTX
KYG596651029
A2JGHF

Price

4.18
Today +/-
-0.16
Today %
-4.22 %
P

MeiraGTx Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the MeiraGTx Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the MeiraGTx Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the MeiraGTx Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze MeiraGTx Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

MeiraGTx Holdings Stock Price History

DateMeiraGTx Holdings Price
9/20/20244.18 undefined
9/19/20244.36 undefined
9/18/20244.29 undefined
9/17/20244.27 undefined
9/16/20244.20 undefined
9/13/20244.25 undefined
9/12/20244.17 undefined
9/11/20244.16 undefined
9/10/20244.07 undefined
9/9/20244.02 undefined
9/6/20243.88 undefined
9/5/20243.92 undefined
9/4/20243.94 undefined
9/3/20243.91 undefined
8/30/20244.07 undefined
8/29/20244.18 undefined
8/28/20244.11 undefined
8/27/20244.09 undefined
8/26/20244.12 undefined
8/23/20244.17 undefined

MeiraGTx Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into MeiraGTx Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MeiraGTx Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MeiraGTx Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of MeiraGTx Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into MeiraGTx Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing MeiraGTx Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MeiraGTx Holdings’s growth potential.

MeiraGTx Holdings Revenue, EBIT and net profit per share

DateMeiraGTx Holdings RevenueMeiraGTx Holdings EBITMeiraGTx Holdings Net Income
2029e972.51 M undefined0 undefined418.42 M undefined
2028e771.53 M undefined321.11 M undefined281.83 M undefined
2027e617.82 M undefined219.4 M undefined192.48 M undefined
2026e208.61 M undefined13.02 M undefined11.81 M undefined
2025e247.57 M undefined119.78 M undefined67.7 M undefined
2024e32.78 M undefined-132.18 M undefined-134.93 M undefined
202314.02 M undefined-137.06 M undefined-84.03 M undefined
202215.92 M undefined-116.36 M undefined-129.62 M undefined
202137.7 M undefined-72.76 M undefined-79.56 M undefined
202015.56 M undefined-62.55 M undefined-57.99 M undefined
201913.29 M undefined-58.27 M undefined-54.75 M undefined
20180 undefined-78.1 M undefined-84.67 M undefined
20170 undefined-31.68 M undefined-31.85 M undefined
20160 undefined-19.46 M undefined-19.57 M undefined

MeiraGTx Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000131537151432247208617771972
----15.38146.67-59.46-6.67128.57671.88-15.79196.6324.9626.07
--------------
00000000000000
-19-31-78-58-62-72-116-137-132119132193210
----446.15-413.33-194.59-773.33-978.57-412.5048.186.2535.4941.63-
-19-31-84-54-57-79-129-84-1346711192281418
-63.16170.97-35.715.5638.6063.29-34.8859.52-150.00-83.581,645.4546.3548.75
27.1827.1818.9533.1637.7244.1445.1856.49000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The MeiraGTx Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the MeiraGTx Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
17.58.568.1227.2209.5137.7115.5129.57
00023.338.522.421.310.14
0001212.912.67.713.28
00000000
1.636.56.511.710.59.86.64
19.111.574.6269272.6183.2154.3159.62
314.32252.987.1126.3154.1156.24
000006.76.36.77
00000000
0000.832.62.11.12
00000000
0.40.10.21.311.41.43
3.414.422.25591.1137163.9167.12
22.525.996.8324363.7320.2318.2326.74
               
32.851.3000000
17.920.1229.1395.6504.5528.7581.9693.84
-34.4-65.4-148.3-203-261-340.6-470.2-554.23
-0.7-20.3-1.8-4.9-2.76-1.44
00000000
15.6481.1190.8238.6185.4117.7138.18
1.57.133.87.115.316.616.04
49.31219.823.43143.746.83
0.53.50.425.723.621.821.84.2
01.4000000
00000000
621.315.449.354.168.182.167.08
0000007172.12
0002002002002000
0.80.40.383.770.866.447.249.37
0.80.40.383.97166.6118.4121.49
6.821.715.7133.2125.1134.7200.5188.57
22.425.796.8324363.7320.1318.2326.74
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of MeiraGTx Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand MeiraGTx Holdings's financial health and stability.

Assets

MeiraGTx Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that MeiraGTx Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of MeiraGTx Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into MeiraGTx Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
-19-31-82-54-57-79-129-84
002247813
00000000
18-457-33319-1
664430415066-6
000000013
00000000
-14-18-5820-63-10-73-105
-2-10-11-8-23-46-44-20
-2-10-11-9-37-61-4434
0000-13-15054
00000000
02-1000750
20161361558712591
20191301488219584
---4.00-7.00-5.00--5.00-7.00
00000000
3-959159-17-71-2215
-16.96-28.6-70.1511.06-87.02-56.88-118.06-125.54
00000000

MeiraGTx Holdings stock margins

The MeiraGTx Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MeiraGTx Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MeiraGTx Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the MeiraGTx Holdings's sales revenue. A higher gross margin percentage indicates that the MeiraGTx Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the MeiraGTx Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the MeiraGTx Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MeiraGTx Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MeiraGTx Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MeiraGTx Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

MeiraGTx Holdings Margin History

MeiraGTx Holdings Gross marginMeiraGTx Holdings Profit marginMeiraGTx Holdings EBIT marginMeiraGTx Holdings Profit margin
2029e0 %0 %43.02 %
2028e0 %41.62 %36.53 %
2027e0 %35.51 %31.15 %
2026e0 %6.24 %5.66 %
2025e0 %48.38 %27.35 %
2024e0 %-403.28 %-411.68 %
20230 %-977.82 %-599.46 %
20220 %-730.9 %-814.2 %
20210 %-193 %-211.03 %
20200 %-401.99 %-372.69 %
20190 %-438.45 %-411.96 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %

MeiraGTx Holdings Stock Sales Revenue, EBIT, Earnings per Share

The MeiraGTx Holdings earnings per share therefore indicates how much revenue MeiraGTx Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MeiraGTx Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MeiraGTx Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MeiraGTx Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MeiraGTx Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MeiraGTx Holdings Revenue, EBIT and net profit per share

DateMeiraGTx Holdings Sales per ShareMeiraGTx Holdings EBIT per shareMeiraGTx Holdings Earnings per Share
2029e12.6 undefined0 undefined5.42 undefined
2028e10 undefined0 undefined3.65 undefined
2027e8 undefined0 undefined2.49 undefined
2026e2.7 undefined0 undefined0.15 undefined
2025e3.21 undefined0 undefined0.88 undefined
2024e0.42 undefined0 undefined-1.75 undefined
20230.25 undefined-2.43 undefined-1.49 undefined
20220.35 undefined-2.58 undefined-2.87 undefined
20210.85 undefined-1.65 undefined-1.8 undefined
20200.41 undefined-1.66 undefined-1.54 undefined
20190.4 undefined-1.76 undefined-1.65 undefined
20180 undefined-4.12 undefined-4.47 undefined
20170 undefined-1.17 undefined-1.17 undefined
20160 undefined-0.72 undefined-0.72 undefined

MeiraGTx Holdings business model

MeiraGTx Holdings PLC is a leading company in the field of gene therapy and develops innovative therapies for various genetic diseases. The company was founded in 2015 and is headquartered in London, UK, with additional locations in the USA. MeiraGTx aims to change lives by developing gene therapy-based drugs that enable a cure or permanent relief from serious illnesses. History: MeiraGTx was founded by renowned genome researcher Dr. Gregory A. Petsko and an experienced team of scientists and experts in the biotechnology and pharmaceutical fields. With an experienced team and significant investment capital, MeiraGTx has established itself as a leading company in the field of gene therapy. Business model: MeiraGTx has a unique business model based on an innovative platform technology that enables the company to develop gene therapies for various diseases. The company works with a variety of technologies, including AAV vectors, DNA targeted integration, gene editing platform, and more. By combining these technologies, MeiraGTx can develop gene therapies tailored to the individual's condition. Segments: MeiraGTx consists of various divisions and products that focus on the development of therapeutics for various genetic diseases. Ophthalmology: MeiraGTx develops gene therapies for retinal diseases such as retinitis pigmentosa and macular degeneration. These therapies have the potential to preserve or even improve vision. Neurology: MeiraGTx develops therapeutics for neurological diseases such as Parkinson's and Huntington's. These gene therapies have the potential to alleviate the symptoms of the disease and improve the patient's quality of life. Hemophilia: MeiraGTx has developed gene therapies for hemophilia A and B based on its gene editing platform technology. These therapies have the potential to significantly improve the lives of hemophilia patients. Other products and therapies: MeiraGTx is also working on the development of gene therapies for cancer, cystic fibrosis, cardiovascular diseases, and autoimmune diseases. Summary: MeiraGTx is a leading company in the field of gene therapy and is committed to developing innovative therapeutics for various genetic diseases. With the help of technologies such as AAV vectors, DNA targeted integration, gene editing platform, and more, the company has the potential to change the lives of millions of patients. MeiraGTx is on track to revolutionize the healthcare industry, and it will be exciting to see what future advances the company will achieve. MeiraGTx Holdings is one of the most popular companies on Eulerpool.com.

MeiraGTx Holdings SWOT Analysis

Strengths

1. Advanced Gene Therapy Portfolio: MeiraGTx Holdings PLC possesses a strong portfolio of cutting-edge gene therapy products, providing potential solutions for various genetic disorders. This portfolio enables the company to offer innovative and effective treatment options for patients.

2. Robust Research and Development: The company heavily invests in research and development activities, driving continuous innovation and ensuring a steady pipeline of novel gene therapy candidates. This commitment to R&D enables MeiraGTx to stay at the forefront of gene therapy advancements.

3. Strategic Partnerships: MeiraGTx has established valuable collaborations with leading academic institutions, medical centers, and pharmaceutical companies. These partnerships facilitate access to additional expertise, resources, and financial support, enhancing the company's capabilities and potential for success.

Weaknesses

1. Limited Commercial Portfolio: While MeiraGTx possesses an impressive gene therapy pipeline, it currently has a limited number of products on the market. The company's success heavily depends on obtaining regulatory approvals and successfully commercializing its candidates, which may pose risks and delays.

2. Reliance on Clinical Trials: MeiraGTx's success is largely dependent on the successful outcomes of its ongoing clinical trials. Any setbacks or negative results during these trials can significantly impact the company's future prospects and investor confidence.

3. Competitive Industry Landscape: The gene therapy market is highly competitive, with numerous companies vying for market share. MeiraGTx faces competition from both established pharmaceutical companies and emerging biotech firms, which may limit its market penetration and growth.

Opportunities

1. Increasing Gene Therapy Demand: As the understanding of genetic disorders and the potential of gene therapy continues to grow, there is an increasing demand for effective gene therapies. MeiraGTx can leverage this trend to expand its market presence and capture a larger share of the growing gene therapy market.

2. Regulatory Support: Regulatory bodies worldwide are recognizing the potential of gene therapy and streamlining processes to expedite approvals. MeiraGTx can benefit from favorable regulatory environments, enabling faster development, approval, and commercialization of its gene therapy candidates.

3. Collaborations and Partnerships: The company can explore additional collaborations and partnerships to diversify its portfolio and access new therapeutic areas. Collaborations can also provide opportunities for shared research and development costs, enhancing MeiraGTx's financial capabilities.

Threats

1. Regulatory and Compliance Challenges: Gene therapy is a complex field, subject to rigorous regulatory oversight. MeiraGTx must navigate through evolving regulations, potential safety concerns, and compliance issues, which can pose challenges and delays during clinical trials and commercialization.

2. Intellectual Property Risks: As a leader in gene therapy, MeiraGTx faces the risk of intellectual property infringements and legal disputes with competitors. Protecting and enforcing its patents and intellectual property rights is crucial to maintaining a competitive advantage in the market.

3. Market Uncertainties: The gene therapy market is still relatively new and evolving. Market dynamics, pricing pressures, and reimbursement policies pose uncertainties that can impact MeiraGTx's financial performance and market growth.

MeiraGTx Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

MeiraGTx Holdings historical P/E ratio, EBIT, and P/S ratio.

MeiraGTx Holdings shares outstanding

The number of shares was MeiraGTx Holdings in 2023 — This indicates how many shares 56.487 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MeiraGTx Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MeiraGTx Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MeiraGTx Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MeiraGTx Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for MeiraGTx Holdings.

MeiraGTx Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.41 -0.76  (-86.27 %)2024 Q2
3/31/2024-0.52 -0.32  (37.88 %)2024 Q1
12/31/2023-0.12 -0.42  (-263.32 %)2023 Q4
9/30/2023-0.56 -0.74  (-32.71 %)2023 Q3
6/30/2023-0.58 -0.53  (8.3 %)2023 Q2
3/31/2023-0.67 -0.62  (7.44 %)2023 Q1
12/31/2022-0.5 -0.6  (-19.43 %)2022 Q4
9/30/2022-0.59 -0.83  (-40.77 %)2022 Q3
6/30/2022-0.66 -0.76  (-15.69 %)2022 Q2
3/31/2022-0.53 -0.7  (-32.63 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the MeiraGTx Holdings stock

Eulerpool World ESG Rating (EESG©)

75/ 100

🌱 Environment

81

👫 Social

76

🏛️ Governance

67

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

MeiraGTx Holdings list of shareholders

%
Name
Stocks
Change
Date
8.60464 % Johnson & Johnson Innovation-JJDC, Inc.6,641,064012/31/2023
6.85620 % Adage Capital Management, L.P.5,291,618620,60112/31/2023
6.08673 % Sanofi SA4,697,7374,697,73710/30/2023
5.24840 % Prosight Capital4,050,714-28,0902/13/2024
4.23271 % Adena Estate Inc.3,266,8063,266,80612/31/2023
3.23918 % 683 Capital Management LLC2,500,00042,39112/31/2023
2.56277 % BlackRock Institutional Trust Company, N.A.1,977,943115,70912/31/2023
14.68140 % Perceptive Advisors LLC11,331,103012/31/2023
1.81587 % Forbes (Alexandria)1,401,489-1,0004/5/2024
1.21285 % Giroux (Richard)936,078-13,5002/29/2024
1
2
3
4
5
...
10

MeiraGTx Holdings Executives and Management Board

Dr. Alexandria Forbes58
MeiraGTx Holdings President, Chief Executive Officer, Director (since 2015)
Compensation 7.72 M
Mr. Richard Giroux50
MeiraGTx Holdings Chief Financial Officer, Chief Operating Officer
Compensation 6.35 M
Dr. Stuart Naylor60
MeiraGTx Holdings Chief Development Officer (since 2015)
Compensation 4.23 M
Mr. Robert Zeldin60
MeiraGTx Holdings Chief Medical Officer
Compensation 4.05 M
Dr. Debra Yu58
MeiraGTx Holdings Independent Director
Compensation 465,967
1
2
3

MeiraGTx Holdings Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,860,10-0,73-0,71-0,71-0,07
Kadmon Holdings, Inc. Stock
Kadmon Holdings, Inc.
SupplierCustomer-0,79-0,85-0,60-0,74-0,62-
1

Most common questions regarding MeiraGTx Holdings

What values and corporate philosophy does MeiraGTx Holdings represent?

MeiraGTx Holdings PLC represents a set of core values and a corporate philosophy aimed at advancing gene therapies for rare diseases and providing innovative solutions. With a focus on building a diversified portfolio, MeiraGTx is committed to scientific excellence, patient advocacy, and collaborative partnerships. The company's vision revolves around bringing transformative treatments to patients in need while maintaining a patient-centric approach. MeiraGTx strives to integrate cutting-edge technologies and research to develop effective gene therapies, leveraging its expertise in gene regulation and optimization. By prioritizing integrity, innovation, and quality, MeiraGTx is dedicated to making a meaningful impact on patients' lives and advancing the field of gene therapy.

In which countries and regions is MeiraGTx Holdings primarily present?

MeiraGTx Holdings PLC primarily operates in the United States and the United Kingdom.

What significant milestones has the company MeiraGTx Holdings achieved?

MeiraGTx Holdings PLC has achieved various significant milestones. The company successfully completed a Phase 1/2 clinical trial for its experimental gene therapy product, AAV-RPGR, which aims to treat inherited retinal diseases. MeiraGTx also received fast track designation from the U.S. FDA for its AAV-RPGR program and secured Orphan Drug Designation for its investigational gene therapy product, AAV-CNGA3, for treating achromatopsia. Furthermore, the company entered into partnership agreements with Janssen Pharmaceuticals and additional collaboration agreements with Johnson & Johnson Innovation and Novartis Institutes for Biomedical Research. MeiraGTx's notable achievements reflect its commitment to advancing innovative therapies in the field of gene therapy.

What is the history and background of the company MeiraGTx Holdings?

MeiraGTx Holdings PLC is a leading clinical-stage gene therapy company. Founded in 2015, the company focuses on developing transformative treatments for various genetic diseases. Headquartered in New York City, MeiraGTx combines expertise in gene therapy, vector design, and manufacturing to advance novel therapies. The company's mission is to deliver life-changing benefits through innovative genetic medicines. With a strong portfolio of product candidates, MeiraGTx aims to address unmet needs in the areas of ophthalmology, salivary gland disorders, neurodegenerative diseases, and more. Through strategic partnerships and collaborations, MeiraGTx continues to make significant advancements in the field of gene therapy.

Who are the main competitors of MeiraGTx Holdings in the market?

The main competitors of MeiraGTx Holdings PLC in the market include companies such as CRISPR Therapeutics AG, Editas Medicine Inc., and Intellia Therapeutics Inc.

In which industries is MeiraGTx Holdings primarily active?

MeiraGTx Holdings PLC is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of MeiraGTx Holdings?

The business model of MeiraGTx Holdings PLC is focused on the development and commercialization of gene therapies. As a biotechnology company, MeiraGTx aims to provide novel treatments for various genetic diseases by utilizing advanced gene therapy techniques. With a strong emphasis on innovation and research, MeiraGTx works towards addressing unmet medical needs in areas such as ophthalmology, neurology, and rare diseases. By leveraging its expertise in gene therapy, the company strives to bring transformative therapies to patients, improving their quality of life and offering potential new treatment options. MeiraGTx Holdings PLC is dedicated to advancing the field of gene therapy through its innovative business model.

What is the P/E ratio of MeiraGTx Holdings 2024?

The MeiraGTx Holdings P/E ratio is -1.75.

What is the P/S ratio of MeiraGTx Holdings 2024?

The MeiraGTx Holdings P/S ratio is 7.2.

What is the AlleAktien quality score of MeiraGTx Holdings?

The AlleAktien quality score for MeiraGTx Holdings is 3/10.

What is the revenue of MeiraGTx Holdings 2024?

The expected MeiraGTx Holdings revenue is 32.78 M USD.

How high is the profit of MeiraGTx Holdings 2024?

The expected MeiraGTx Holdings profit is -134.93 M USD.

What is the business model of MeiraGTx Holdings

MeiraGTx Holdings PLC is a leading company in the development of gene and cell therapies for patients with rare genetic diseases as well as for patients with hereditary retinal diseases that can lead to blindness. The company is divided into different divisions to focus on the two areas of gene and cell therapy. In the gene therapy division, MeiraGTx offers a range of products for a variety of diseases. For example, the company offers gene therapy for hemophilia B, where a defective gene is replaced that is necessary for blood clotting. In the cell therapy division, MeiraGTx is focused on developing therapies for hereditary retinal diseases. The company has global exclusive rights to market a product called AAV-RPGR. This product is an adeno-associated virus (AAV) that delivers a healthy copy of the RPGR gene into retinal cells. This therapeutic method is used to treat X-linked retinitis pigmentosa (XLRP), a rare disease that can lead to blindness. MeiraGTx utilizes a combination of proprietary and licensed technology. The company has an extensive library of adeno-associated viruses (AAV) that offer high efficiency and safety. MeiraGTx also collaborates closely with academics and researchers to accelerate progress in gene and cell therapy. MeiraGTx's business model is based on a proven approach to developing therapies for rare genetic diseases and hereditary retinal diseases. However, the development of these therapies is costly and involves lengthy clinical trials. To overcome this financial challenge, MeiraGTx has attracted investors who have a keen interest in this emerging field of medicine. Another component of MeiraGTx's business model is partnering with biopharmaceutical industry partners. For example, the company has formed a strategic partnership with Janssen Pharmaceutica NV, a Johnson & Johnson company. Under this agreement, MeiraGTx is working on the development of gene therapies for certain central nervous system disorders. Successful partnerships and collaboration with established pharmaceutical companies can help reduce the risk and cost of developing new therapies. Overall, MeiraGTx is a company built on a solid scientific foundation and focused on developing innovative medicines for rare genetic diseases and hereditary retinal diseases. The company's business model relies on a combination of proprietary and licensed technology, investor funding, and strategic partnerships. MeiraGTx has the potential to improve the lives of millions of people worldwide.

What is the MeiraGTx Holdings dividend?

MeiraGTx Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does MeiraGTx Holdings pay dividends?

The dividend cannot currently be calculated for MeiraGTx Holdings or the company does not pay out a dividend.

What is the MeiraGTx Holdings ISIN?

The ISIN of MeiraGTx Holdings is KYG596651029.

What is the MeiraGTx Holdings WKN?

The WKN of MeiraGTx Holdings is A2JGHF.

What is the MeiraGTx Holdings ticker?

The ticker of MeiraGTx Holdings is MGTX.

How much dividend does MeiraGTx Holdings pay?

Over the past 12 months, MeiraGTx Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MeiraGTx Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of MeiraGTx Holdings?

The current dividend yield of MeiraGTx Holdings is .

When does MeiraGTx Holdings pay dividends?

MeiraGTx Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of MeiraGTx Holdings?

MeiraGTx Holdings paid dividends every year for the past 0 years.

What is the dividend of MeiraGTx Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is MeiraGTx Holdings located?

MeiraGTx Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von MeiraGTx Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of MeiraGTx Holdings from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did MeiraGTx Holdings pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of MeiraGTx Holdings in the year 2023?

In the year 2023, MeiraGTx Holdings distributed 0 USD as dividends.

In which currency does MeiraGTx Holdings pay out the dividend?

The dividends of MeiraGTx Holdings are distributed in USD.

All fundamentals about MeiraGTx Holdings

Our stock analysis for MeiraGTx Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MeiraGTx Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.